CMS has released its proposed rule for 2019 Medicare physician reimbursement.

This Weekly’s Hot Topic’s

  • The United States Food and Drug Administration has announced a biosimilar action plan. (National News)
  • CMS has released its proposed rule for 2019 Medicare physician reimbursement. (CMS News)

The United States Food and Drug Administration has announced a biosimilar action plan that is meant to spur biosimilar competition by addressing four key areas: improving the efficiency of the biosimilar and interchangeable product development and approval process; maximizing scientific and regulatory clarity for the biosimilar product development community. For more information click here and go to National News.

CMS has released its proposed rule for 2019 Medicare physician reimbursement. CMS estimates that in 2019, overall impact for the hematology/oncology specialty will be a -4% reduction in reimbursement and a -2% reduction for radiation oncology. For more information click here and go to CMS News.

CMS has announced that participants in the Merit-based Incentive Payment System (MIPS) for 2017 can review their MIPS final score and performance feedback onto Quality Payment Program. For more information click here and go to CMS News.

ASCO has opened two Guidelines for comment. The two Guidelines are: Early Detection for Colorectal Cancer: ASCO Resource-Stratified Guideline and Treatment of Non-Metastatic Colorectal Cancer: ASCO Resource-Stratified Guideline. Both comment periods end July 27.  For more information click here and got to Affiliate Association News.

To view the complete California Oncology Weekly Newsletter, click on the date below.

July 24, 2018

 



No comments have been posted yet.